During the past decade, Chu de Grenoble Hôpital Albert Michallon conducted 120 clinical trials. In the 10-year time frame, 120 clinical trials started and 39 clinical trials were completed, i.e. on average, 32.5% percent of trials that started reached the finish line to date. In the past 5 years, 50 clinical trials started and 28 clinical trials were completed. i.e. 56% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chu de Grenoble Hôpital Albert Michallon" #1 sponsor was "Boston Scientific Corporation" with 12 trials, followed by "Celgene" with 9 trials sponsored, "Assistance Publique - Hôpitaux de Paris" with 7 trials sponsored, "Groupe Francophone des Myelodysplasies" with 7 trials sponsored and "Hospices Civils de Lyon" with 7 trials sponsored. Other sponsors include 172 different institutions and companies that sponsored additional 110 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chu de Grenoble Hôpital Albert Michallon" #1 collaborator was "Celgene Corporation" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 4 trials as a collaborator, "Hoffmann-La Roche" with 4 trials as a collaborator, "Ministry of Health, France" with 3 trials as a collaborator and "National Cancer Institute, France" with 3 trials as a collaborator. Other collaborators include 90 different institutions and companies that were collaborators in the rest 87 trials.

According to Clinical.Site data, the most researched conditions in "Chu de Grenoble Hôpital Albert Michallon" are "Multiple Myeloma" (8 trials), "Myelodysplastic Syndromes" (7 trials), "Pulmonary Arterial Hypertension" (7 trials), "Breast Cancer" (6 trials) and "Atrial Fibrillation" (5 trials). Many other conditions were trialed in "Chu de Grenoble Hôpital Albert Michallon" in a lesser frequency.

Most popular intervention types in "Chu de Grenoble Hôpital Albert Michallon" are "Drug" (141 trials), "Device" (34 trials), "Biological" (21 trials), "Other" (21 trials) and "Procedure" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Dexamethasone" (6 trials), "Carboplatin" (4 trials), "Docetaxel" (4 trials) and "Lenalidomide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Chu de Grenoble Hôpital Albert Michallon" are 204 trials for "All" genders, 12 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Chu de Grenoble Hôpital Albert Michallon". undefined are not yet recruiting, 35 are recruiting, 25 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 123 completed trials in Chu de Grenoble Hôpital Albert Michallon, 1 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Chu de Grenoble Hôpital Albert Michallon, 9 "Phase 1" clinical trials were conducted, 63 "Phase 2" clinical trials and 82 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 30 trials that are defined as “Not Applicable".

Chu de Grenoble Hôpital Albert Michallon has several departments that took part in Clinical trials: "Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie" - 22 trials, "Hopital Albert Michallon; Gastro Enterologie" - 2 trials